Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$5.36 +1.7%	$5.30	$2.20 ▼ $6.20	$192.75M	1.5	8,470 shs	16,816 shs
JSPR Jasper Therapeutics	$2.80 -1.4%	$3.63	$2.27 ▼ $26.05	$45.50M	2.77	215,849 shs	94,742 shs
MDWD MediWound	$16.70 -0.7%	$19.02	$14.14 ▼ $22.50	$180.53M	0.25	100,029 shs	163,477 shs
VYGR Voyager Therapeutics	$3.36 -1.2%	$3.29	$2.64 ▼ $8.27	$186.38M	0.9	732,356 shs	203,262 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	0.00%	+1.52%	+1.06%	+36.04%	+110.20%
JSPR Jasper Therapeutics	0.00%	-4.44%	-2.78%	-48.62%	-87.16%
MDWD MediWound	0.00%	-5.11%	-9.88%	-24.91%	-9.19%
VYGR Voyager Therapeutics	0.00%	-2.04%	+13.51%	+2.13%	-48.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPRX Eupraxia Pharmaceuticals	2.2552 of 5 stars	3.6	1.0	0.0	2.7	0.0	0.6
JSPR Jasper Therapeutics	3.2751 of 5 stars	4.3	4.0	0.0	1.5	1.7	0.6
MDWD MediWound	1.4592 of 5 stars	3.4	1.0	0.0	1.6	0.8	0.6
VYGR Voyager Therapeutics	3.5847 of 5 stars	3.6	1.0	4.6	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	105.22% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	926.79% Upside
MDWD MediWound	2.80	Moderate Buy	$32.25	93.11% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.25	294.26% Upside

Current Analyst Ratings Breakdown

Latest JSPR, MDWD, VYGR, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/19/2025	MDWD MediWound	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
8/7/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
MDWD MediWound	$20.22M	8.93	N/A	N/A	$2.89 per share	5.78
VYGR Voyager Therapeutics	$80M	2.33	N/A	N/A	$5.49 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.85	N/A	N/A	N/A	N/A	-367.73%	-126.38%	11/6/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$6.01	N/A	N/A	N/A	N/A	-172.28%	-128.34%	11/6/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.64	N/A	N/A	N/A	-142.18%	-96.71%	-39.73%	N/A
VYGR Voyager Therapeutics	-$65M	-$1.85	N/A	N/A	N/A	-253.49%	-37.65%	-28.89%	11/11/2025 (Estimated)

Latest JSPR, MDWD, VYGR, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/12/2025	Q2 2025	EPRX Eupraxia Pharmaceuticals	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A
8/6/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$9.50 million	$5.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	N/A	8.72	8.72
JSPR Jasper Therapeutics	N/A	2.10	2.10
MDWD MediWound	N/A	1.48	1.35
VYGR Voyager Therapeutics	N/A	5.43	5.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
JSPR Jasper Therapeutics	79.85%
MDWD MediWound	46.83%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
JSPR Jasper Therapeutics	4.60%
MDWD MediWound	9.20%
VYGR Voyager Therapeutics	4.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
JSPR Jasper Therapeutics	20	16.25 million	15.51 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
VYGR Voyager Therapeutics	100	55.47 million	52.96 million	Optionable

JSPR, MDWD, VYGR, and EPRX Headlines

Recent News About These Companies

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Average Price Target from Analysts

August 27, 2025 | americanbankingnews.com

Voyager to Present at Upcoming Investor Conferences

August 26, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

August 26, 2025 | marketbeat.com

Voyager Therapeutics Extends Cash Runway to 2028

August 13, 2025 | msn.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

August 11, 2025 | theglobeandmail.com

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

August 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for VYGR Q3 Earnings

August 11, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 10, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

August 9, 2025 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at Wedbush

August 8, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025 | globenewswire.com

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

Uranus Heat Readings Contradict 40-Year-Old Voyager 2 Results

July 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, MDWD, VYGR, and EPRX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.36 +0.09 (+1.71%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$5.54 +0.18 (+3.26%)

As of 08/29/2025 07:15 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Jasper Therapeutics NASDAQ:JSPR

$2.80 -0.04 (-1.41%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.05 (+1.61%)

As of 08/29/2025 07:51 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

MediWound NASDAQ:MDWD

$16.70 -0.12 (-0.71%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$16.67 -0.03 (-0.18%)

As of 08/29/2025 04:10 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Voyager Therapeutics NASDAQ:VYGR

$3.36 -0.04 (-1.18%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.42 +0.06 (+1.79%)

As of 08/29/2025 04:30 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time